230 related articles for article (PubMed ID: 14692656)
1. Potent killing of paclitaxel- and doxorubicin-resistant breast cancer cells by calphostin C accompanied by cytoplasmic vacuolization.
Guo B; Hembruff SL; Villeneuve DJ; Kirwan AF; Parissenti AM
Breast Cancer Res Treat; 2003 Nov; 82(2):125-41. PubMed ID: 14692656
[TBL] [Abstract][Full Text] [Related]
2. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
3. Essential role of c-Jun-NH2-terminal kinase on synergy induction of apoptosis by TRAIL plus ADM in ADM resistant MCF-7/ADM cells.
Li F; Meng L; Xing H; Zhou J; Wang S; Huang L; Xu G; Zhu H; Lu Y; Ma D
Apoptosis; 2006 Jul; 11(7):1239-46. PubMed ID: 16703262
[TBL] [Abstract][Full Text] [Related]
4. Cell death induced by taxanes in breast cancer cells: cytochrome C is released in resistant but not in sensitive cells.
Ehrlichová M; Koc M; Truksa J; Naldová Z; Václavíková R; Kovárr J
Anticancer Res; 2005; 25(6B):4215-24. PubMed ID: 16309219
[TBL] [Abstract][Full Text] [Related]
5. Role of specific apoptotic pathways in the restoration of paclitaxel-induced apoptosis by valspodar in doxorubicin-resistant MCF-7 breast cancer cells.
Chadderton A; Villeneuve DJ; Gluck S; Kirwan-Rhude AF; Gannon BR; Blais DE; Parissenti AM
Breast Cancer Res Treat; 2000 Feb; 59(3):231-44. PubMed ID: 10832593
[TBL] [Abstract][Full Text] [Related]
6. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
Park SJ; Wu CH; Safa AR
Anticancer Res; 2004; 24(1):123-31. PubMed ID: 15015586
[TBL] [Abstract][Full Text] [Related]
7. Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure.
Guo B; Villeneuve DJ; Hembruff SL; Kirwan AF; Blais DE; Bonin M; Parissenti AM
Breast Cancer Res Treat; 2004 May; 85(1):31-51. PubMed ID: 15039596
[TBL] [Abstract][Full Text] [Related]
8. Drug-resistant breast carcinoma (MCF-7) cells are paradoxically sensitive to apoptosis.
Chen JS; Konopleva M; Andreeff M; Multani AS; Pathak S; Mehta K
J Cell Physiol; 2004 Aug; 200(2):223-34. PubMed ID: 15174092
[TBL] [Abstract][Full Text] [Related]
9. Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells.
Ehrlichova M; Vaclavikova R; Ojima I; Pepe A; Kuznetsova LV; Chen J; Truksa J; Kovar J; Gut I
Naunyn Schmiedebergs Arch Pharmacol; 2005 Jul; 372(1):95-105. PubMed ID: 16059735
[TBL] [Abstract][Full Text] [Related]
10. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
Keane MM; Ettenberg SA; Nau MM; Russell EK; Lipkowitz S
Cancer Res; 1999 Feb; 59(3):734-41. PubMed ID: 9973225
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460.
Huisman C; Ferreira CG; Bröker LE; Rodriguez JA; Smit EF; Postmus PE; Kruyt FA; Giaccone G
Clin Cancer Res; 2002 Feb; 8(2):596-606. PubMed ID: 11839682
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of SALL4 inhibits the proliferation and reverses the resistance of MCF-7/ADR cells to doxorubicin hydrochloride.
Chen YY; Li ZZ; Ye YY; Xu F; Niu RJ; Zhang HC; Zhang YJ; Liu YB; Han BS
BMC Mol Biol; 2016 Mar; 17():6. PubMed ID: 26935744
[TBL] [Abstract][Full Text] [Related]
15. Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells.
Prados J; Melguizo C; Rama AR; Ortiz R; Segura A; Boulaiz H; Vélez C; Caba O; Ramos JL; Aránega A
Cancer Chemother Pharmacol; 2010 May; 66(1):69-78. PubMed ID: 19771430
[TBL] [Abstract][Full Text] [Related]
16. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines.
Chu E; Drake JC; Koeller DM; Zinn S; Jamis-Dow CA; Yeh GC; Allegra CJ
Mol Pharmacol; 1991 Feb; 39(2):136-43. PubMed ID: 1704999
[TBL] [Abstract][Full Text] [Related]
17. Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis.
Yang XH; Sladek TL; Liu X; Butler BR; Froelich CJ; Thor AD
Cancer Res; 2001 Jan; 61(1):348-54. PubMed ID: 11196185
[TBL] [Abstract][Full Text] [Related]
18. Comparison of cell death-inducing effect of novel taxane SB-T-1216 and paclitaxel in breast cancer cells.
Kovár J; Ehrlichová M; Smejkalová B; Zanardi I; Ojima I; Gut I
Anticancer Res; 2009 Aug; 29(8):2951-60. PubMed ID: 19661300
[TBL] [Abstract][Full Text] [Related]
19. The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels.
Ruiz de Almodóvar C; Ruiz-Ruiz C; Muñoz-Pinedo C; Robledo G; López-Rivas A
Oncogene; 2001 Oct; 20(48):7128-33. PubMed ID: 11704839
[TBL] [Abstract][Full Text] [Related]
20. Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.
Wang H; Vo T; Hajar A; Li S; Chen X; Parissenti AM; Brindley DN; Wang Z
BMC Cancer; 2014 Jan; 14():37. PubMed ID: 24447372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
